Syneos Health to Present at the UBS Virtual Global Healthcare Conference
Syneos Health (Nasdaq: SYNH) will have CEO Alistair Macdonald and CFO Jason Meggs present at the UBS Virtual Global Healthcare Conference on May 19, 2020, at 9:10 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syneos Health (Nasdaq: SYNH) will have CEO Alistair Macdonald and CFO Jason Meggs present at the UBS Virtual Global Healthcare Conference on May 19, 2020, at 9:10 a.m. ET. The event aims to discuss strategies and performance in the biopharmaceutical sector. A live webcast of the presentation, along with supplementary materials and an archived audio replay, can be accessed via the company's Investor Relations website. Syneos Health operates as a fully integrated biopharmaceutical solutions organization, combining CRO and CCO capabilities to enhance customer performance globally.
Details
News Market Reaction – SYNH
The recorded move for SYNH in the trading session of this news was -3.19%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., May 13, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that Chief Executive Officer Alistair Macdonald and Chief Financial Officer Jason Meggs are scheduled to present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020, at 9:10 a.m. ET.
A live webcast of the event, along with a link to the presentation materials and archived audio replay of the presentation, will be available on the Company’s Investor Relations website at investor.syneoshealth.com.
About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.
Contacts
Investor Relations:
Ronnie Speight
Senior Vice President, Investor Relations
+1 919 745 2745
Investor.Relations@syneoshealth.com
Press/Media:
Danielle DeForge
Executive Director, External Communications
+1 202 210 5992
danielle.deforge@syneoshealth.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.